Investigation of VEGGIE Root Mat

VEGGIE is a plant growth facility that utilizes the phenomenon of capillary action as its primary watering system. A cloth made of Meta Aramid fiber, known as Nomex is used to wick water up from a reservoir to the bottom of the plants roots. This root mat system is intended to be low maintenance with no moving parts and requires minimal crew interface time. Unfortunately, the water wicking rates are inconsistent throughout the plant life cycle, thus causing plants to die. Over-wicking of water occurs toward the beginning of the cycle, while under-wicking occurs toward the middle. This inconsistency of wicking has become a major issue, drastically inhibiting plant growth. The primary objective is to determine the root cause of the inconsistent wicking through experimental testing. Suspect causes for the capillary water column to break include: a vacuum effect due to a negative pressure gradient in the water reservoir, contamination of material due to minerals in water and back wash from plant fertilizer, induced air bubbles while using syringe refill method, and material limitations of Nomex's ability to absorb and retain water. Experimental testing will be conducted to systematically determine the cause of under and over-wicking. Pressure gages will be used to determine pressure drop during the course of the plant life cycle and during the water refill process. A debubbler device will be connected to a root mat in order to equalize pressure inside the reservoir. Moisture and evaporation tests will simultaneously be implemented to observe moisture content and wicking rates over the course of a plant cycle. Water retention tests will be performed using strips of Nomex to determine materials wicking rates, porosity, and absorptivity. Through these experimental tests, we will have a better understanding of material properties of Nomex, as well as determine the root cause of water column breakage. With consistent test results, a forward plan can be achieved to resolve the issue and give valuable insight for the next generation of VEGGIE

インドにおけるオープンアクセスと機関リポジトリ

DRFIC2008 Session 1. Open Access and Institutional Repository in Asia-PacificDRFIC2008 セッション1:アジア・環太平洋地域におけるオープンアクセスと機関リポジトリ 報告

Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications.

Ewing sarcoma occurs in children, adolescents and young adults. High STAT3 levels have been reported in approximately 50% of patients with Ewing sarcoma, and may be important in tumorigenesis. Protein tyrosine phosphatase delta (PTPRD) is a tumor suppressor that inhibits STAT3 activation. To date, while somatic mutations in PTPRD have been reported in diverse tumors, germline mutations of PTPRD have not been investigated in Ewing sarcoma or other cancers. We identified a novel germline mutation in the PTPRD gene in three of eight patients (37.5%) with metastatic Ewing sarcoma. Although the functional impact in two of the patients is unclear, in one of them the aberration was annotated as a W775stop germline mutation, and would be expected to lead to gene truncation and, hence, loss of the STAT3 dephosphorylation function of PTPRD. Since STAT3 is phosphorylated after being recruited to the insulin growth factor receptor (IGF-1R), suppression of IGF-1R could attenuate the enhanced STAT3 activation expected in the presence of PTPRD mutations. Of interest, two of three patients with germline PTPRD mutations achieved durable complete responses following treatment with IGF-1R monoclonal antibody-based therapies. Our pilot data suggest that PTPRD germline mutations may play a role in the development of Ewing sarcoma, a disease of young people, and their presence may have implications for therapy

Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials.

PurposePatients with advanced cholangiocarcinoma (CC) and gallbladder carcinoma (GC) have few therapeutic options for relapsed disease. methods: Given the overall poor prognosis in this population and the availability of novel targeted therapies, we systematically analyzed the characteristics and outcomes for GC and CC patients treated on phase I trials with an emphasis on targeted agents and locoregional therapies.ResultsOf 40 treated patients (GC=6; CC=34; median age, 60 years), 8 (20%) had stable disease (SD) > 6 months, 3 (8%) partial response (PR), on protocols with hepatic arterial drug infusion and anti-angiogenic, anti-HER-2/neu or novel MAPK/ERK kinase (MEK) inhibitors. Median progression-free survival (PFS) on phase I trials was 2.0 months (95% CI 1.7, 2.8) versus 3.0 months (95% CI 2.4, 5.0), 3.0 months (95% CI 2.3, 4.6), and 3.0 months (95% CI 2.4, 3.9) for their first-, second-, and last-line FDA-approved therapy. In univariate analysis, >3 metastatic sites, elevated alanine aminotransferase (ALT) (>56IU/L), serum creatinine (>1.6mg/dL), and CA19-9 (>35U/mL) were associated with a shorter PFS. Mutational analysis revealed mutation in the KRAS oncogene in 2 of 11 patients (18%). The SD >6 months/PR rate of 28% was seen with hepatic arterial infusion of oxaliplatin, and inhibitors of angiogenesis, HER-2/neu or MEK.ConclusionsThe PFS in phase I trials was similar to that of the first, second, and last-line therapy (P=0.95, 0.98, 0.76, respectively) with FDA-approved agents given in the advanced setting, emphasizing a role for targeted agents in a clinical trials setting as potentially valuable therapeutic options for these patients

Transparent metal electrodes from ordered nanosphere arrays

We show that perforated metal electrode arrays, fabricated using nanosphere lithography, provide a viable alternative to conductive metal oxides as transparent electrode materials. The inter-aperture spacing is tuned by varying etching times in an oxygen plasma, and the effect of inter-aperture “wire” thickness on the optical and electronic properties of perforated silver films is shown. Optical transmission is limited by reflection and surface plasmons, and for these results do not exceed 73%. Electrical sheet resistance is shown to be as low as 3 Ω ◻−1 for thermally evaporated silver films. The performance of organic photovoltaic devices comprised of a P3HT:PCBM bulk heterojunction deposited onto perforated metal arrays is shown to be limited by optical transmission, and a simple model is presented to overcome these limitations

Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1).

BackgroundDesmoplastic small round cell tumor (DSRCT) is a rare sarcoma in adolescents and young adults. The hallmark of this disease is a EWS-WT1 translocation resulting from apposition of the Ewing's sarcoma (EWS) gene with the Wilms' tumor (WT1) gene. We performed morphoproteomic profiling of DSRCT (EWS-WT1), Ewing's sarcoma (EWS-FLI1) and Wilms' tumor (WT1) to better understand the signaling pathways for selecting future targeted therapies.MethodologyThis pilot study assessed patients with DSRCT, Wilms' tumor and Ewing's sarcoma. Morphoproteomics and immunohistochemical probes were applied to detect: p-mTOR (Ser2448); p-Akt (Ser473); p-ERK1/2 (Thr202/Tyr204); p-STAT3 (Tyr 705); and cell cycle-related analytes along with their negative controls.Principal findingsIn DSRCT the PI3K/Akt/mTOR pathway is constitutively activated by p-Akt (Ser 473) expression in the nuclear compartment of the tumor cells and p-mTOR phosphorylated on Ser 2448, suggesting mTORC2 (rictor+mTOR) as the dominant form. Ewing's sarcoma had upregulated p-Akt and p-mTOR, predominantly mTORC2. In Wilm's tumor, the mTOR pathway is also activated with most tumor cells moderately expressing p-mTOR (Ser 2448) in plasmalemmal and cytoplasmic compartments. This coincides with the constitutive activation of one of the downstream effectors of the mTORC1 signaling pathway, namely p-p70S6K (Thr 389). There was constitutive activation of the Ras/Raf/ERK pathway p-ERK 1/2 (Thr202/Tyr204) expression in the Wilms tumor and metastatic Ewing's sarcoma, but not in the DSRCT.ConclusionMORPHOPROTEOMIC TUMOR ANALYSES REVEALED CONSTITUTIVE ACTIVATION OF THE MTOR PATHWAY AS EVIDENCED BY: (a) expression of phosphorylated (p)-mTOR, p-p70S6K; (b) mTORC 2 in EWS and DSRCT; (c) ERK signaling was seen in the advanced setting indicating these as resistance pathways to IGF1R related therapies. This is the first morphoproteomic study of such pathways in these rare malignancies and may have potential therapeutic implications. Further study using morphoproteomic assessments of these tumors are warranted

A New Approach in Manufacturing of Reverse Vending Machine

Reverse vending machine is a concept or an idea which inculcate the habit of recycling the waste materials. Reverse vending machine will be working by taking recyclable waste into the machine and gives a use full thing as a token of appreciation. The aim of this project is to design and fabricate a reverse vending machine which takes recyclable waste into the machine and displays a token of appreciation. The machine can accept a plastic bottle of 90mm diameter without cap and tin cans can be accepted and crushed and stored. The machine has a capacity of storing 50 plastic bottles and 50 tin cans. There basically two parts, one is the mechanical part and the other is the electronics part. The mechanical part is used to crush the recyclable waste which is kept in the machine so that more plastic and cans can be recycled and stored. The electronics part which consist of sensor and microcontroller, is used to take the correct input and segregate the waste into its respective categories and give a token of appreciation as a LCD display. The whole system is automated by the help of electronics. Combining both parts will give a reverse vending machine. Reverse vending machine will be working by taking recyclable waste into the machine and gives a use full thing as a token of appreciation. With limited resources in the world, we need to start preserving them and put an end to wastage. Being encouraged to recycle through a rewards system.To encourage recycling process we are designing and manufacturing reverse vending machine

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.

Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II dose (RP2D), and dose-limiting toxicities (DLTs) of combined mTOR inhibitor sirolimus (1 mg-5 mg PO daily) and HDAC inhibitor vorinostat (100 mg-400 mg PO daily) in patients with advanced cancer. Seventy patients were enrolled and 46 (66%) were evaluable for DLT assessment since they completed cycle 1 without dose modification unless they had DLT. DLTs comprised grade 4 thrombocytopenia (n = 6) and grade 3 mucositis (n = 1). Sirolimus 4 mg and vorinostat 300 mg was declared RP2D because MTD with sirolimus 5 mg caused significant thrombocytopenia. The grade 3 and 4 drug-related toxic effects (including DLTs) were thrombocytopenia (31%), neutropenia (8%), anemia (7%), fatigue (3%), mucositis (1%), diarrhea (1%), and hyperglycemia (1%). Of the 70 patients, 35 (50%) required dose interruption or modification and 61 were evaluable for response. Partial responses were observed in refractory Hodgkin lymphoma (-78%) and perivascular epithelioid tumor (-54%), and stable disease in hepatocellular carcinoma and fibromyxoid sarcoma. In conclusion, the combination of sirolimus and vorinostat was feasible, with thrombocytopenia as the main DLT. Preliminary anticancer activity was observed in patients with refractory Hodgkin lymphoma, perivascular epithelioid tumor, and hepatocellular carcinoma